Overview

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness, safety and tolerability of the drug combination: gemcitabine, carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian cancer, fallopian tube or primary peritoneal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborators:
Eli Lilly and Company
Genentech, Inc.
Treatments:
Bevacizumab
Carboplatin
Gemcitabine